CDK9-IN-44 (Compound 7) is a selective CDK9 inhibitor (IC50=7.6 µM). CDK9-IN-44 inhibits CDK9/cyclin T1 kinase activity, blocking transcriptional elongation, reducing the expression of pro-cancer proteins (such as MCL1, c-MYC), and inducing tumor cell apoptosis. CDK9-IN-44 is promising for research of glioblastoma (GBM) and central nervous system (CNS) disorders[1].
Molecular Weight:
394.37
Formula:
C22H18O7
Target:
CDK
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
